SMIM13 (UPF0766) as a Drug Target and Biomarker for the Treatment of Proteolytic Encephalopathies

Target Name: SMIM13

NCBI ID: G221710

Other Name(s): UPF0766 protein C6orf228 | Small integral membrane protein 13 | SIM13_HUMAN | small integral membrane protein 13 | C6orf228

SMIM13 (UPF0766) as a Drug Target and Biomarker for the Treatment of Proteolytic Encephalopathies

Proteolytic encephalopathies (PEDs) are a group of rare, progressive neurodegenerative diseases caused by the progressive loss of protein synthesis in the brain. These diseases are characterized by the accumulation of misfolded proteins, including neurotransmitter-converting enzymes, which cause the progressive neurotoxicity associated with the disease. One of the most promising strategies to develop new treatments for PEDs is to target the misfolded proteins that are responsible for the neurotoxicity. In this article, we will discuss the protein C6orf228 (SMIM13) as a potential drug target and biomarker for the treatment of PEDs.

SMIM13 (Superfamily-Membership-Involving Module 13) is a protein that is expressed in a variety of tissues, including brain, heart, and liver. It is a member of the superfamily of proteins known as the SMIM family, which are characterized by the presence of a specific module called the \"TIR domain.\" The TIR domain is a conserved region that is involved in the formation of protein-protein interactions and in the regulation of protein stability.

SMIM13 has been shown to play a role in the regulation of a variety of cellular processes, including cell signaling, DNA replication, and protein folding. It has also been shown to be involved in the development and progression of a variety of diseases, including neurodegenerative diseases.

As a potential drug target, SMIM13 has been the focus of research in recent years, with a number of studies showing that it can be targeted with small molecules and antibodies to induce protein misfolding and enhance neurotoxicity. These studies have led to the identification of a number of potential drug candidates that can be tested in animal models of PEDs.

SMIM13 has also been shown to be a potential biomarker for the diagnosis and monitoring of PEDs. The misfolded proteins that are accumulating in PEDs cause a variety of neurotoxicity, including the progressive loss of protein synthesis, the accumulation of neurotransmitter-converting enzymes, and the progressive neurotoxicity associated with the disease. By targeting SMIM13, researchers may be able to develop new diagnostic tests and monitoring tools for PEDs.

Conclusion

SMIM13 is a protein that has the potential to be a drug target and biomarker for the treatment of PEDs. Its role in the regulation of cellular processes and its involvement in the development and progression of a variety of diseases make it an attractive target for research into the treatment of these debilitating conditions. As further studies continue to explore the potential of SMIM13 as a drug and biomarker, researchers may be able to develop new treatments for PEDs that can improve the quality of life for patients.

Protein Name: Small Integral Membrane Protein 13

More Common Targets